Background
Calprotectin, a S100 protein Calprotectin is a complex of two calcium-binding proteins that belong to the S100 protein family 1 . It is abundant in the cytosolic fraction of neutrophils. High levels of calprotectin have been found in extracellular fluid during various inflammatory conditions, such as rheumatoid arthritis, cystic fibrosis and abscesses. Calprotectin released from neutrophils has growth-inhibitory and apoptosis-inducing activities against various cell types including tumor cells and normal fibroblasts 1 . This suggests that calprotectin has regulatory activities during inflammatory processes through its effect on the survival or growth states of cells participating in the inflammatory reaction. Furthermore, calprotectin inhibits microbial growth through competition for zinc 2 . Calprotectin has been shown to be stable in feces during storage for 7 days at room temperature, which is very important for its value in evaluating mucosal wall inflammation 3 .
Stool Calprotectin Levels as Marker of Intestinal Inflammation
Fecal Calprotectin has been shown to consistently differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) because it has an excellent negative predictive value in ruling out IBD in undiagnosed, symptomatic patients 4 .
Convincing studies and growing clinical experience point to an expanded role in the diagnosis and management of IBD. A total 602 new referrals to a gastroenterology clinic who had symptoms suggestive of IBS or organic intestinal diseases underwent invasive imaging and other investigations as appropriate. Data correlated to fecal Calprotectin showed a sensitivity and specificity of Calprotectin for organic disease of 89% and 79%, respectively 5 . This indicates that fecal calprotectin provides a safe and noninvasive marker to differentiate between patients with organic and non-organic intestinal disease 6 . Fecal calprotectin levels correlate significantly with histological and endoscopic assessment of disease activity in ulcerative colitis (UC) [6] [7] [8] as well as with fecal alpha-1-antitrypsin levels and fecal excretion of 111indium-labeled white blood cells in patients with Crohn's disease (CD) 9, 10 . Schoepfer and colleagues showed that stool calprotectin levels correlate well with endoscopic indices both in ulcerative colitis and in Crohn's disease 11, 12 .
Diagnostic delay in IBD is predictive for worse disease progression and outcomes Diagnosing IBD can be a considerable challenge, especially in cases with mild clinical activity due to the overlap of symptoms with functional diseases. Indeed, symptoms similar to irritable bowel syndrome (IBS) are frequently reported in patients before IBD is diagnosed 13 . Difficulties in differentiation early IBD from IBS, especially in a primary care setting, is leading to a considerable diagnostic delay in IBD 14 . Diagnostic delay has important clinical impact, as there is increasing evidence demonstrating that treatment success is increased in early disease [15] [16] [17] [18] [19] . Vavricka and colleagues suggest, that diagnostic delay is sub-dived into two intervals, where interval 1 is defined as time from first symptoms to physician visit, and interval the time from first physician visit to IBD diagnosis 14 . The study by Vavricka et al suggests, that 25% of all CD and UC patients wait from first onset of symptoms more than 24 and 12 months, respectively, for their accurate IBD diagnosis 14 . Most importantly Schoepfer and colleagues recently showed, that the length of diagnostic delay is correlated with an increased risk of bowel stenosis and CD-related intestinal surgery, concluding that efforts should be undertaken to shorten the diagnostic delay 21 .
ALERT Study Protocol 4
Testing calprotectin in Switzerland Most analytical laboratories in Switzerland offer calprotectin testing, which is reimbursed by health insurances.
Hypothesis and goal
Although calprotectin test are easily accessible and reimbursed in Switzerland, the diagnostic value for early detection of intestinal inflammation is not yet recognized in primary care setting, leading to a significant diagnostic delay 14 .
This study pursuits two main goals A and B, which are investigated independently: A. Retrospective validation and evaluation of sensitivity and specificity of an 8-item IBDquestionnaire (CalproQuest; see addendum) for 1) a positive Calprotectin test result ≥ 50 μg/ml feces and for 2) a positive Calprotectin test result ≥ 50 μg/ml feces and positive IBD-diagnosis, respectively. B. Prospective implementation of CalproQuest in primary care to investigate feasibility in daily practice.
Methods and study design
Study design This study is a mono-centric diagnostic observational trial. The study consists of two independent and consecutive parts A and B, conducted by gastroenterologists (A) and general practitioners (B), respectively. Patients included in part A of the study are referred to the gastroenterologist for endoscopic evaluation for any reason. Patients included in part B of the study present at their family doctor because of on-going unspecific gastrointestinal symptoms (abdominal pain, bloating, stool irregularities, chronic diarrhea) for at least two weeks. The study design and procedure are summarized in the addendum (see study design).
Inclusion and exclusion criteria Patients will be eligible if they Procedure of the study In brief, the study will be divided in two independent parts A and B, conducted by gastroenterologists (A) and general practitioners (B), respectively. Patient data will be encoded.
A. Investigation of the sensitivity and specificity of CalproQuest for stool Calprotectin levels ≥ 50 μg/ml feces and for positive IBD diagnosis 162 patients referred to the gastroenterologist for endoscopic examination are subjected to CalproQuest and Calprotectin stool testing prior endoscopy, if all inclusion criteria are met and informed patient consent is obtained. At baseline T0, patients will be subjected to CalproQuest. Subsequently, at T1 fecal samples will be obtained to measure calprotectin levels. The patients themselves will perform collection of the fecal specimens. The fecal specimens from outpatients will be shipped to the laboratory at the University Hospital Zurich by mail. After measurement, fecal samples will be disposed according to current guidelines. At T2, endoscopic examination will be performed to obtain a diagnosis. Eventually, patients diagnosed with IBD will be asked to complete a questionnaire at T3 investigating duration of first onset of symptoms to IBD diagnosis (diagnostic delay).
B. Investigation of feasibility of CalproQuest in daily primary care practice
80 patients with on-going unspecific gastrointestinal symptoms (abdominal pain, bloating, stool irregularities, chronic diarrhea) for more than two weeks presenting at the general practitioner (n=27) will be included into the study if all inclusion criteria are met and informed patient consent is obtained. At baseline T0, patients will be subjected to CalproQuest. Subsequently, at T1 fecal samples will be obtained to measure calprotectin levels. The patients themselves will perform collection of the fecal specimens. The fecal specimens from outpatients will be shipped to the laboratory at the University Hospital Zurich by mail. After measurement, fecal samples will be disposed according to current guidelines. According to the current standard of care patients with calprotectin levels ≥ 50 μg/ml will be referred to a gastroenterologist for endoscopic examination at T2; results of the endoscopy are communicated back to the general practitioner. Eventually, patients will be asked at T3 to complete a questionnaire on acceptance of stool sampling, and physicians will complete the questionnaire on feasibility of CalproQuest in daily practice.
Time frame
The study is intended to last 14 months, from which the recruitment time will be 12 months and the intervention 2 months.
CalproQuest
CalproQuest is an 8-item IBD-questionnaire consisting of 4 main and 4 secondary questions specific for IBD (see addendum). CalproQuest was pre-validated by IBD-experts trough an international Delphi-process. CalproQuest is considered positive, if ≥ 2 main criteria are answered positively or 1 main criterion and 2 secondary criteria are answered positively. We assume that a positive CalproQuest result may predict Calprotectin levels ≥ 50 μg/ml. Calprotectin levels above 50 μg/ml are indicative for on-going intestinal inflammation and call for further endoscopic examination.
Fecal calprotectin
Fecal Calprotectin levels will be measured at the University Hospital Zurich by a novel ELISA-based calprotectin test named EliA Caprotectin (Thermo Scientific, for product description see http://www.phadia.com/PageFiles/29347/Product%20information%20EliA%20Calprotectin.pdf).
Patient questionnaire on diagnostic delay Three relevant time intervals of diagnostic delay will be assessed in a patient questionnaire (see addendum). The time intervals are defined as follows: 1. Interval 1: Time from first IBD symptoms to consultation with the general practitioner: This interval represents the time span between the first manifestations of IBD-related symptoms (patient-reported) and a consultation with the family physician specifically due to these IBDrelated complaints. The length of this period is mainly dependent on the patient herself/himself. 2. Interval 2: Time from family physician visit to referral to a gastroenterologist: This represents the time span between the IBD symptom-related consultation of the family physician and the time of referral to a gastroenterologist for further examination. The length of this period is mainly dependent on the treating family physicians. 3. Interval 3: Time from first IBD symptoms to IBD diagnosis (interval 1+2): This interval is calculated by the addition of interval 1 and 2 and is defined as diagnostic delay. Diagnostic delay is defined as the time span (in weeks) from first symptoms to IBD diagnosis.
The following items in the patient questionnaires are assessed for the purpose of this study: ''Before the IBD diagnosis, how long did you experience symptoms that are now attributed to IBD?'' and ''How long was the time interval between first symptoms and the first visit to your family physician?'' and "How long were you treated by your family physician before referral to a gastroenterologist?" and ''What was the time span from the first physician visit (due to these complaints) until IBD diagnosis was established?'' Additionally, patients will answer questions regarding smoking habits, intake of nonsteroidal anti-inflammatory drugs (NSAIDs), or oral contraception at the time of diagnosis.
Physician questionnaire on feasibility and acceptance of CalproQuest in primary care Goal of the feasibility questionnaire is to investigate feasibility and acceptance of CalproQuest in daily primary care practice (for questionnaire: see addendum). The questionnaire is based on an even-point Likert scale consisting of seven Likert items.
Patient questionnaire on acceptance of stool sampling Goal of the acceptance questionnaire is to investigate patients' physical and mental ability to handle stool sampling at home (for questionnaire: see addendum). The questionnaire is based on an even-point Likert scale consisting of four Likert items.
Administration of patient records Physicians will be supplied with a master data list providing patient codes that can be assigned to the patient. All documents containing patient data will carry the respective patient code assigned by the physician. Encoded documents will be sent to the Institute für Hausarztmedizin, Universitätsspital Zürich, and stored for 10 years. Only physicians have access to the patient codes.
Statistical analysis
Sample size calculation Sample size was calculated according to Flahault et al. 22 . Assuming a 0.05 two-sided significance level, n=162 would have 90 % power to detect a sensitivity and specificity of 90% of CalproQuest for a calprotectin level ≥ 50 μg/ml feces, or for a calprotectin level ≥ 50 μg/ml feces and a positive IBD diagnosis. For the purpose of this this calculation, expected sensitivity and specificity are 90% with a lower acceptable limit of sensitivity of 70%. Assumed prevalence of IBD within the sample is 20%. A p<0.05 is considered statistically significant.
Statistical data evaluation
We provide sensitivity and specificity calculation of CalproQuest based on confidence intervals. 
